Kennedy Capital Management’s AnaptysBio ANAB Stock Holding History

Kennedy Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-27,196	Closed	-$1.93M	–	718
2018 Q2	$1.93M	Sell	27,196 -446	-2%	-$37.4K	0.04%	601
2018 Q1	$2.88M	Sell	27,642 -22,324	-45%	-$2.52M	0.06%	543
2017 Q4	$5.03M	Sell	49,966 -48,167	-49%	-$3.55M	0.09%	421
2017 Q3	$3.43M	Buy	+98,133	New	+$2.65M	0.06%	533

Other funds holding ANAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Kennedy Capital Management's ANAB Position: Q3 2018 in Review

Kennedy Capital Management sold out of AnaptysBio (ANAB) in Q3 2018, closing a stake of 27,196 shares — an estimated $1.93M sold.

Kennedy Capital Management first reported a position in ANAB in Q3 2017 and held it in 4 quarters. The position peaked at $5.03M in Q4 2017. 129 funds tracked by Wall St. Rank hold ANAB as of Q3 2018.

Kennedy Capital Management reported no remaining AnaptysBio position as of Q3 2018 after selling out during the quarter.
Kennedy Capital Management sold 27,196 AnaptysBio shares in Q3 2018, an estimated $1.93M.
Kennedy Capital Management first reported a position in AnaptysBio in Q3 2017 and held it in 4 quarters.
Kennedy Capital Management's AnaptysBio position peaked at $5.03M in Q4 2017.
129 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2018.

Based on Kennedy Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.